, /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today unveiled ExellenSÂ – an optimized manufacturing framework applied across the company's biomanufacturing network. Developed through Samsung Biologics' cumulative expertise in plant design, digitalization, and operational excellence, ExellenSstandardizes equipment, processes, and functional specifications to ensure that every facility operates with the same precision. The framework ...

Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [3] Upcoming Financial Results - Lifecore will report its financial results for the fourth quarter and fiscal year 2025 on August 7, 2025, after market close [1] - A webcast hosted by Lifecore's senior management team will take place at 4:30 p.m. Eastern Time on the same day to discuss the results [1][2] Webcast Access - Investors can listen to the live webcast or access the archived version on Lifecore's Investor Events & Presentations page [2] - The archived version will be available for 30 days following the live event [2] Contact Information - Lifecore's investor relations contact is Stephanie Diaz from Vida Strategic Partners, reachable at 415-675-7401 [4] - Media inquiries can be directed to Tim Brons at 415-675-7402 [4] - Ryan D. Lake serves as the CFO of Lifecore Biomedical and can be contacted at 952-368-6244 [4]

Core Viewpoint - BGM Group Ltd is undergoing a significant leadership transition aimed at enhancing its technological transformation and sustainable growth, with a focus on innovation and strategic upgrades in response to market opportunities and challenges [1][5]. Leadership Changes - Mr. Zhanchang Xin has resigned as Chairman, effective March 1, 2025, and will be succeeded by Mr. Chen Xin, the current CEO [2][3]. - Mr. Chen Xin has extensive experience in market consolidation and corporate management, having led the acquisition of Duxiaobao Intelligent Technology and previously worked in autonomous driving algorithm development [3][4]. - Mr. Lin Zhang has been appointed as an independent director and will chair the compensation committee, bringing rich experience in AI model architecture and deep learning projects [4][5]. Strategic Focus - The company is strategically focused on technology fields including AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [6]. - BGM Group utilizes big data mining and AI Agent technology to provide comprehensive AI solutions and intelligent robot services, particularly in the insurance sector [7]. - In biopharmaceuticals, the company produces key products like oxytetracycline API and crude heparin sodium, integrating AI-assisted decision-making to optimize production and supply chain processes [8].